JP7500083B2 - 細胞含有医薬組成物 - Google Patents
細胞含有医薬組成物 Download PDFInfo
- Publication number
- JP7500083B2 JP7500083B2 JP2021541368A JP2021541368A JP7500083B2 JP 7500083 B2 JP7500083 B2 JP 7500083B2 JP 2021541368 A JP2021541368 A JP 2021541368A JP 2021541368 A JP2021541368 A JP 2021541368A JP 7500083 B2 JP7500083 B2 JP 7500083B2
- Authority
- JP
- Japan
- Prior art keywords
- macrophages
- cells
- cell population
- cell
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2019/032322 WO2021033247A1 (ja) | 2019-08-19 | 2019-08-19 | 細胞含有医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021033247A1 JPWO2021033247A1 (cg-RX-API-DMAC7.html) | 2021-02-25 |
| JPWO2021033247A5 JPWO2021033247A5 (cg-RX-API-DMAC7.html) | 2022-08-26 |
| JP7500083B2 true JP7500083B2 (ja) | 2024-06-17 |
Family
ID=74659865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541368A Active JP7500083B2 (ja) | 2019-08-19 | 2019-08-19 | 細胞含有医薬組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12460182B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7500083B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102791419B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021033247A1 (cg-RX-API-DMAC7.html) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6372782B2 (ja) | 2012-09-28 | 2018-08-15 | 公益財団法人神戸医療産業都市推進機構 | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014027474A1 (ja) | 2012-08-17 | 2014-02-20 | 株式会社Clio | 心筋梗塞の修復再生を誘導する多能性幹細胞 |
| AU2015297347B2 (en) | 2014-08-01 | 2021-05-27 | PuREC Co., Ltd | Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method |
| US20160287638A1 (en) | 2015-04-02 | 2016-10-06 | Stemedica Cell Technologies, Inc. | Ischemic tolerant cells and cellular factors in the treatment of peripheral artery disease |
| EP3297615A1 (en) * | 2015-05-20 | 2018-03-28 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for modulation polarization and activation of macrophages |
| EP3299453B1 (en) * | 2016-09-23 | 2019-05-08 | Xcell Medical Solutions, S.L. | Cell therapy with polarized macrophages for tissue regeneration |
-
2019
- 2019-08-19 US US17/612,441 patent/US12460182B2/en active Active
- 2019-08-19 WO PCT/JP2019/032322 patent/WO2021033247A1/ja not_active Ceased
- 2019-08-19 JP JP2021541368A patent/JP7500083B2/ja active Active
- 2019-08-19 KR KR1020217037758A patent/KR102791419B1/ko active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6372782B2 (ja) | 2012-09-28 | 2018-08-15 | 公益財団法人神戸医療産業都市推進機構 | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 |
Non-Patent Citations (2)
| Title |
|---|
| CHENG Z. et al.,Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis.,Cellular Immunology,2017年,Vol.311,p.46-53 |
| MASUDA H. et al.,J. Am. Heart Assoc.,2014年,Vol.3,e000743 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220003564A (ko) | 2022-01-10 |
| WO2021033247A1 (ja) | 2021-02-25 |
| JPWO2021033247A1 (cg-RX-API-DMAC7.html) | 2021-02-25 |
| KR102791419B1 (ko) | 2025-04-08 |
| US20220218744A1 (en) | 2022-07-14 |
| US12460182B2 (en) | 2025-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dazzi et al. | The role of mesenchymal stem cells in haemopoiesis | |
| US10722541B2 (en) | Methods for treating radiation or chemical injury | |
| Schatteman et al. | Biology of bone marrow-derived endothelial cell precursors | |
| US8747905B2 (en) | Therapeutic use of CD31 expressing cells | |
| Kim et al. | Cultured human bone marrow–derived CD31+ cells are effective for cardiac and vascular repair through enhanced angiogenic, adhesion, and anti-inflammatory effects | |
| JP7599953B2 (ja) | 造血幹細胞を生成するための方法 | |
| JP2002500879A (ja) | 幹細胞の精製ポピュレーション | |
| US10874698B2 (en) | Therapy using cardiac stem cells and mesenchymal stem cells | |
| JP2023504573A (ja) | 造血幹細胞を生成するための方法 | |
| JP2024515690A (ja) | 疾患の治療のための間葉系間質細胞からの細胞外小胞 | |
| US6821513B1 (en) | Method for enhancing hematopoiesis | |
| JPWO2020158924A1 (ja) | 母児間免疫寛容を誘導する方法 | |
| Rivera-Torruco et al. | Exploring extramedullary hematopoiesis: unraveling the hematopoietic microenvironments | |
| CN114901806B (zh) | 细胞群以及其取得方法 | |
| Tamura et al. | In vivo differentiation of stem cells in the aorta-gonad-mesonephros region of mouse embryo and adult bone marrow | |
| Madariaga et al. | Kidney‐Induced Cardiac Allograft Tolerance in Miniature Swine is Dependent on MHC‐Matching of Donor Cardiac and Renal Parenchyma | |
| KR20230154177A (ko) | 림프관 신생촉진인자 발현 섬유아세포 및 이를 포함하는의약 조성물 | |
| JP2002523039A (ja) | 非胎児血管芽細胞を含む細胞集団、およびその生産方法 | |
| KR102791419B1 (ko) | 세포 함유 의약 조성물 | |
| WO2007047963A2 (en) | Use of bone-marrow derived stem cells to treat ischemia | |
| WO2009046058A1 (en) | A method to amplify cardiac stem cells in vitro and in vivo | |
| US9901639B2 (en) | Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease | |
| Jozkowicz et al. | Vasculogenesis—a new strategy for induction of peripheral neovascularization | |
| Efimenko et al. | Viability and angiogenic activity of mesenchymal stromal cells from adipose tissue and bone marrow under hypoxia and inflammation in vitro | |
| Gupte | Pluripotent Hematopoietic Stem Cells Augment α-Adrenergic Receptor-Mediated 1 Contraction of Pulmonary Artery and Contribute to the Pathogenesis of Pulmonary 2 Hypertension 3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20220218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220818 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230919 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240529 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7500083 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |